Literature DB >> 35000879

Evaluation of thorax computed tomographic findings in COVID-19 variant cases.

F Dilek Gökharman1, Günay Tuncer Ertem2, Sonay Aydın3, Ayşe Büyükdemirci2, Esra Yüksekkaya2, Oğuzhan Tokur4, Pınar N Koşar4.   

Abstract

BACKGROUND: Because of genetic mutations occurring during viral replication, new SARS-CoV-2 variants will continue to emerge. Throughout the COVID-19 pandemic, thorax computed tomographic (CT) findings have played a crucial role in the diagnosis and follow-up of patients with COVID-19. In this study, we compared the thorax CT findings of patients infected with SARS-CoV-2 variants (variant group) with those of patients infected with the non-variant strain (non-variant group) to assess if thorax CT findings may be utilized to discriminate between the groups. Furthermore, we compared demographic and laboratory data between the groups.
METHODS: The study comprised a total of 77 patients who presented to our hospital with a preliminary diagnosis of COVID-19 based on clinical symptoms, a positive oropharyngeal/nasopharyngeal swab RT-PCR testing, and thorax CT examinations. Patients' laboratory and demographic features as well as thorax CT findings were retrospectively evaluated, and the results were grouped according to RT-PCR results.
RESULTS: There were 42 patients in the non-variant group and 35 patients in the variant group. The average age of patients infected with the non-variant strain, alpha variant, and gamma variant was 63.52 ± 14.87 years, 54.86 ± 14.31 years, and 59.4 ± 17.79 years, respectively. The average age of the variant group was significantly lower than that of the non-variant group. There was no significant difference in thorax CT findings between the groups, and consolidation, ground glass densities, and cobblestone pattern in the bilateral lower lobes and peripheral areas were the most common thorax CT findings in both the groups.
CONCLUSION: There is no significant difference in thorax CT findings between the variant and non-variant groups. Therefore, clinical and laboratory characteristics should take precedence over thorax CT findings for distinguishing between patients infected with SARS-CoV-2 variants and the non-variant strain.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  COVID-19; Pandemic; Thorax CT; Variant

Mesh:

Year:  2022        PMID: 35000879      PMCID: PMC8723831          DOI: 10.1016/j.resinv.2021.11.013

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


Introduction

Throughout the ongoing coronavirus disease 2019 (COVID-19) pandemic, numerous SARS-CoV-2 variants have emerged. Among them, both the alpha and beta/gamma variants have been found in Turkey. In a study by Dao et al., the clinical findings of patients infected with SARS-CoV-2 variants (variant group) and the non-variant strain (non-variant group) were compared, and the incidence rates of fever, rhinitis, and anosmia and hospitalization rate were found to be significantly higher in the variant group than those in the non-variant group [1]. Because each variant has a different impact on morbidity and mortality and raises concerns about the performance of vaccines, it's critical to distinguish between their properties early on [2,3]. Thorax computed tomographic (CT) findings have been reported to be useful for the diagnosis, prognostic assessment, and detection of complications of COVID-19 infection [4]. CT severity score assessed based on the percentage of lung involvement has been shown to be a good prognostic predictor in patients with COVID-19 [5]. Using dual energy CT (DECT), another study has shown an association between lung perfusion deficits and CT severity score [6]. Therefore, for the diagnosis of COVID-19, thorax CT imaging is commonly combined with real-time polymerase chain reaction (RT-PCR) using nasal swab as specimen. In this study, we compared the thorax CT findings of the variant group with those of the non-variant group to assess if thorax CT findings could be used to distinguish between the two groups. To the best of our knowledge, this is the first study in the English literature that compares variant strains and the non-variant strain in terms of thorax CT findings and laboratory results.

Materials and methods

This retrospective observational study was undertaken at a tertiary health care facility in Turkey between January 1, 2021 and May 1, 2021. Patients who were hospitalized with fever and the clinical symptoms of respiratory tract infection (e.g., cough and shortness of breath) and patients who had a positive RT-PCR result for SARS-CoV-2 and thorax CT scan were included in this study. Eight hospitalized patients who did not undergo thorax CT examinations or had negative RT-PCR results for SARS-CoV-2 were excluded from the study. On admission, oropharyngeal/nasopharyngeal swabs of all patients were analyzed using RT-PCR to detect SARS CoV-2 RNA. RT-PCR can detect the mutations in both the alpha and beta/gamma variants. All patients in our hospital underwent thorax CT examinations using 16-slice and 128-slice CT scanners within 10 days after diagnosis, and CT images were assessed retrospectively by experts blinded to RT-PCR results. In addition, patients' laboratory and demographic findings were evaluated retrospectively; the results were classified into two groups based on RT-PCR results and compared between the groups. Informed consent was obtained from all patients, and the study protocol was approved by the Institutional Ethics Committee of Ankara Training and Research Hospital, Ankara, Turkey (approval no.: 649; September 15, 2021).

Statistical analysis

Data were analyzed using Statistical Package for the Social Sciences (SPSS) software version 20.0 for Windows (IBM SPSS Inc., Chicago, IL, USA). Conformity of the data to normal distribution was assessed using the Kolmogorov-Smirnov test. Normally distributed and non-normally distributed quantitative variables were presented as mean ± standard deviation (SD) and median (range), respectively. Categorical variables were expressed as number and percentage. Differences between the variant and non-variant groups were analyzed using the Student's t-test and Mann—Whitney U test. The chi-square test was used to compare the percentages of findings between the groups. A two tailed p value of <0.05 was considered statistically significant.

Results

The study population consisted of 77 patients with a median age of 60 years (range 18–92). There were 43 (55.8%) male patients. There were 42 (54.5%) patients in the non-variant group and 35 (45.5 %) patients in the variant group. The variant group had 30 (85.7%) cases of the alpha variant and 5 (14.2%) cases of the beta/gamma variants. Table 1 shows patients' demographic characteristics.
Table 1

Patients' demographic characteristics.

GroupVariantPatientsaSexa
Age (years)b
FemaleMale
VariantAlpha variant30(%39)9(%11,7)21(%27,3)54.86 ± 14.31
Beta/gamma variants5(%6,5)2(%2,6)3(%3.9)59.4 ± 17.79
Non-variant42(%54,5)23(%29,9)19(%24,6)63.52 ± 14.87

Data are presented as number (percentage).

Data are presented as mean ± standard deviation.

Patients' demographic characteristics. Data are presented as number (percentage). Data are presented as mean ± standard deviation. The mean age of patients infected with the non-variant strain, alpha variant, and gamma variant was 63.52 ± 14.87 years, 54.86 ± 14.31 years, and 59.4 ± 17.79 years, respectively. The mean age of the variant group was significantly lower than that of the non-variant group (p = 0.003) (Table 1). There was no difference in sex between the groups (p = 0.11) (Table 1). Although the median levels of C-reactive protein (CRP) and D-dimer in the non-variant group were significantly higher than those in the variant group (p = 0.002), there were no significant differences in leukocyte and lymphocyte counts between the groups (p = 0.23) (Table 2 ).
Table 2

Laboratory findings of the variant and non-variant groups.

GroupLaboratory findings
WBCa count (10⁹/L)Lymphocyte count (10⁹/L)CRPb level (mg/L)D-dimer level (ng/mL)
Variant5700120018450
Non-variant562599538765

White blood cell = WBC.

C-reactive protein = CRP.

Laboratory findings of the variant and non-variant groups. White blood cell = WBC. C-reactive protein = CRP. Only five (6.5%) patients had no CT findings. Among them, two patients belonged to the variant group (one patient infected with the alpha variant one patient infected with the beta variant), and three patients were in the non-variant group (Fig. 1, Fig. 2 ).
Fig. 1

Non-variant group: Thorax computed tomographic (CT) images of a 59-year-old male patient in the non-variant group show patchy ground glass densities (arrows) and some consolidations at the periphery of both the lungs (asterisk). He had a CT severity index of 72.

Fig. 2

Variant group: Thorax CT images of a 38-year-old male patient in the variant group (alpha variant) showing bilateral peripheral-weighted patchy ground glass densities (arrows) similar to those observed in the non-variant group. He had a CT severity index of 44.

Non-variant group: Thorax computed tomographic (CT) images of a 59-year-old male patient in the non-variant group show patchy ground glass densities (arrows) and some consolidations at the periphery of both the lungs (asterisk). He had a CT severity index of 72. Variant group: Thorax CT images of a 38-year-old male patient in the variant group (alpha variant) showing bilateral peripheral-weighted patchy ground glass densities (arrows) similar to those observed in the non-variant group. He had a CT severity index of 44. No significant differences were observed in bilateral (p = 0.53) and multilobar involvement (p = 0.39), ground glass densities and/or the presence of consolidated areas, and CT severity index values (p = 0.43) between the groups; the lower lobes were the most affected lobes in both the groups (Fig. 1, Fig. 2). Other signs of COVID-19 infection in the lungs such as vascular enlargement, cobblestone appearance, halo sign, and air bubble showed no significant differences between the groups.

Discussion

COVID-19 has spread worldwide since it was first detected in December 2019. Because of the rapid dissemination of SARS-CoV-2, new strains have emerged. Among them, the alpha variant and beta variant are the most well-known ones. The impact of variants on clinical manifestations and prognostic outcomes affects the early diagnosis and treatment of patients with COVID-19 and, most importantly, the preventative approaches to reduce viral circulation in the population [7]. The most common symptoms of COVID-19 are fever, dry cough, and malaise/fatigue. Many studies have found that COVID-19 infection causes a reduction in white blood cell (WBC) and lymphocyte counts and an increase in CRP and D-dimer levels [[8], [9], [10], [11], [12], [13]]. On the other hand, Amano et al. observed that a lower WBC count was indicative of COVID-19, but lymphocytopenia and D-dimer level were poor predictors of COVID-19 [14]. Typical thorax CT features of COVID-19 pneumonia have also been reported. Bilateral involvement of the basal segments of the lower lobes and peripheral areas is indicative of lung involvement. Patchy ground glass densities, areas of consolidation, cobblestone pattern, and a combination of these features are the most prevalent thorax CT findings in patients with COVID-19 [15]. In a meta-analysis, Khatami et al. reported that the sensitivity and specificity of thorax CT were 83% and 47%, respectively; they also suggested that thorax CT might contribute to the diagnosis of COVID-19 [16]. To the best of our knowledge, no other study in the English literature compares laboratory results between the two groups. Real-time polymerase chain reaction (RT-PCR) is the most widely used method for detecting virus variants. However, it may not produce correct results in the presence of some mutations, causing diagnostic delays. The diagnostic role of thorax CT in COVID-19 is well understood, and thorax CT has become a significant approach for rapid diagnosis and prognosis of COVID-19 although it is not recommended as the first step in the diagnosis of COVID-19 [[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17]]. This is the first study in the English literature that compares thorax CT findings between patients infected with variant strains and the non-variant strain. In this study, we evaluated the efficacy of CT imaging in distinguishing different variants of SARS-CoV-2. We also compared demographic and laboratory features between the groups. According to our findings, there is no significant difference in thorax CT findings between the groups. The non-variant group had significantly higher median CRP and D-dimer levels than the variant group. Furthermore, the mean age of the variant group was significantly greater than that of the non-variant group. Other findings of the groups were similar. The study has some limitations. First, this was retrospective study. Second, the inclusion criteria may introduce bias since only patients with COVID-19-like symptoms and thorax CT scans were included in this study. Patients with clinically suspected COVID-19 who had no thorax CT findings and patients who had clinical and thorax CT findings indicating COVID-19 infection but had negative RT-PCR results were excluded from the study. Third, this study included a small number of patients. Therefore, further studies with large sample size are required to confirm the results of this study.

Conclusion

Our findings indicate that thorax CT findings do not differ significantly between the variant and non-variant groups. Therefore, clinical and laboratory features should take precedence over thorax CT findings for distinguishing among SARS-CoV-2 variants.

Ethics approval and consent to participate

The study was approved by the Institutional Ethics Committee of Ankara Training and Research Hospital, Ankara, Turkey (approval no.: 649; September 15, 2021), and written informed consent was obtained from all patients.

Conflict of Interest

The authors have no conflicts of interest.
  17 in total

1.  D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study.

Authors:  Yumeng Yao; Jiatian Cao; Qingqing Wang; Qingfeng Shi; Kai Liu; Zhe Luo; Xiang Chen; Sisi Chen; Kaihuan Yu; Zheyong Huang; Bijie Hu
Journal:  J Intensive Care       Date:  2020-07-10

2.  Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients With Coronavirus Disease 2019.

Authors:  Zijie Shen; Yan Xiao; Lu Kang; Wentai Ma; Leisheng Shi; Li Zhang; Zhuo Zhou; Jing Yang; Jiaxin Zhong; Donghong Yang; Li Guo; Guoliang Zhang; Hongru Li; Yu Xu; Mingwei Chen; Zhancheng Gao; Jianwei Wang; Lili Ren; Mingkun Li
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

Review 3.  Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings.

Authors:  Ebrahim Abbasi-Oshaghi; Fatemeh Mirzaei; Farhad Farahani; Iraj Khodadadi; Heidar Tayebinia
Journal:  Int J Surg       Date:  2020-05-15       Impact factor: 6.071

4.  Diagnostic prediction of COVID-19 based on clinical and radiological findings in a relatively low COVID-19 prevalence area.

Authors:  Yosuke Amano; Hidenori Kage; Goh Tanaka; Wataru Gonoi; Yudai Nakai; Ryo Kurokawa; Shohei Inui; Koh Okamoto; Sohei Harada; Masato Iwabu; Yutaka Morizaki; Osamu Abe; Kyoji Moriya; Takahide Nagase
Journal:  Respir Investig       Date:  2021-03-29

5.  Covid-19 vaccines and new mutant strains impacting the pandemic.

Authors:  Shanker Matta; Sanjay Rajpal; K K Chopra; V K Arora
Journal:  Indian J Tuberc       Date:  2021-04

6.  A meta-analysis of accuracy and sensitivity of chest CT and RT-PCR in COVID-19 diagnosis.

Authors:  Fatemeh Khatami; Mohammad Saatchi; Seyed Saeed Tamehri Zadeh; Zahra Sadat Aghamir; Alireza Namazi Shabestari; Leonardo Oliveira Reis; Seyed Mohammad Kazem Aghamir
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

7.  Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis.

Authors:  Marco Francone; Franco Iafrate; Giorgio Maria Masci; Simona Coco; Francesco Cilia; Lucia Manganaro; Valeria Panebianco; Chiara Andreoli; Maria Chiara Colaiacomo; Maria Antonella Zingaropoli; Maria Rosa Ciardi; Claudio Maria Mastroianni; Francesco Pugliese; Francesco Alessandri; Ombretta Turriziani; Paolo Ricci; Carlo Catalano
Journal:  Eur Radiol       Date:  2020-07-04       Impact factor: 5.315

8.  Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China.

Authors:  Lingli Li; Lian Yang; Shan Gui; Feng Pan; Tianhe Ye; Bo Liang; Yu Hu; Chuansheng Zheng
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

9.  Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France.

Authors:  Thi Loi Dao; Van Thuan Hoang; Nhu Ngoc Nguyen; Jérémy Delerce; Hervé Chaudet; Anthony Levasseur; Jean Christophe Lagier; Didier Raoult; Philippe Colson; Philippe Gautret
Journal:  Clin Microbiol Infect       Date:  2021-05-24       Impact factor: 13.310

Review 10.  Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?

Authors:  Ivana Lazarevic; Vera Pravica; Danijela Miljanovic; Maja Cupic
Journal:  Viruses       Date:  2021-06-22       Impact factor: 5.048

View more
  2 in total

1.  Comparison of temporal evolution of computed tomography imaging features in COVID-19 and influenza infections in a multicenter cohort study.

Authors:  Tim Fischer; Yassir El Baz; Giulia Scanferla; Nicole Graf; Frederike Waldeck; Gian-Reto Kleger; Thomas Frauenfelder; Jens Bremerich; Sabine Schmidt Kobbe; Jean-Luc Pagani; Sebastian Schindera; Anna Conen; Simon Wildermuth; Sebastian Leschka; Carol Strahm; Stephan Waelti; Tobias Johannes Dietrich; Werner C Albrich
Journal:  Eur J Radiol Open       Date:  2022-06-24

Review 2.  The Role of Ionizing Radiation for Diagnosis and Treatment against COVID-19: Evidence and Considerations.

Authors:  Marina Chalkia; Nikolaos-Achilleas Arkoudis; Emmanouil Maragkoudakis; Stamatis Rallis; Ioanna Tremi; Alexandros G Georgakilas; Vassilis Kouloulias; Efstathios Efstathopoulos; Kalliopi Platoni
Journal:  Cells       Date:  2022-01-29       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.